These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 28734027)

  • 1. Chronic kidney disease as a risk factor for recurrence and progression in patients with primary non-muscle-invasive bladder cancer.
    Kobatake K; Hayashi T; Black PC; Goto K; Sentani K; Kaneko M; Yasui W; Mita K; Teishima J; Matsubara A
    Int J Urol; 2017 Aug; 24(8):594-600. PubMed ID: 28734027
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impaired estimated glomerular filtration rate is a significant predictor for non-muscle-invasive bladder cancer recurrence and progression--introducing a novel prognostic model for bladder cancer recurrence.
    Rausch S; Hennenlotter J; Todenhöfer T; Aufderklamm S; Schwentner C; Sievert KD; Stenzl A; Gakis G
    Urol Oncol; 2014 Nov; 32(8):1178-83. PubMed ID: 24962661
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chronic kidney disease as an important risk factor for tumor recurrences, progression and overall survival in primary non-muscle-invasive bladder cancer.
    Li CE; Chien CS; Chuang YC; Chang YI; Tang HP; Kang CH
    Int Urol Nephrol; 2016 Jun; 48(6):993-9. PubMed ID: 26995008
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preoperative chronic kidney disease is predictive of oncological outcome of radical cystectomy for bladder cancer.
    Matsumoto A; Nakagawa T; Kanatani A; Ikeda M; Kawai T; Miyakawa J; Taguchi S; Naito A; Otsuka M; Nakanishi Y; Suzuki M; Koga F; Nagase Y; Kondo Y; Okaneya T; Tanaka Y; Miyazaki H; Fujimura T; Fukuhara H; Kume H; Igawa Y; Homma Y
    World J Urol; 2018 Feb; 36(2):249-256. PubMed ID: 29185045
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reduced estimated glomerular filtration rate (eGFR <60 mL/min/1.73 m
    Blute ML; Kucherov V; Rushmer TJ; Damodaran S; Shi F; Abel EJ; Jarrard DF; Richards KA; Messing EM; Downs TM
    BJU Int; 2017 Sep; 120(3):387-393. PubMed ID: 28464520
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic Factors for Recurrence and Progression in Korean Non-Muscle-Invasive Bladder Cancer Patients: A Retrospective, Multi-Institutional Study.
    Kim HS; Ku JH; Kim SJ; Hong SJ; Hong SH; Kim HS; Kwon TG; Cho JS; Jeon SS; Joo KJ; Ahn HJ; Park HS; Seong do H; Kwon DD; Kim HJ; Lim JS; Lee HL
    Yonsei Med J; 2016 Jul; 57(4):855-64. PubMed ID: 27189277
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Can re-cTURBT be useful in pT1HG disease as a risk indicator of recurrence and progression? A single centre experience.
    Giulianelli R; Gentile BC; Mirabile G; Albanesi L; Tariciotti P; Rizzo G; Buscarini M; Vermiglio M
    Arch Ital Urol Androl; 2017 Dec; 89(4):272-276. PubMed ID: 29473376
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic Value of Serum Cholinesterase in Non-muscle-invasive Bladder Cancer.
    Kimura S; Soria F; D'Andrea D; Foerster B; Abufaraj M; Vartolomei MD; Karakiewicz PI; Mathieu R; Moschini M; Rink M; Egawa S; Shariat SF; Gust KM
    Clin Genitourin Cancer; 2018 Dec; 16(6):e1123-e1132. PubMed ID: 30061034
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preoperative chronic kidney disease predicts poor prognosis in patients with primary non-muscle-invasive bladder cancer who underwent transurethral resection of bladder tumor.
    Fujita N; Hatakeyama S; Momota M; Tobisawa Y; Yoneyama T; Yamamoto H; Imai A; Ito H; Yoneyama T; Hashimoto Y; Yoshikawa K; Ohyama C
    Urol Oncol; 2020 Aug; 38(8):684.e1-684.e8. PubMed ID: 32201059
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ki-67 is an independent indicator in non-muscle invasive bladder cancer (NMIBC); combination of EORTC risk scores and Ki-67 expression could improve the risk stratification of NMIBC.
    Ding W; Gou Y; Sun C; Xia G; Wang H; Chen Z; Tan J; Xu K; Qiang D
    Urol Oncol; 2014 Jan; 32(1):42.e13-9. PubMed ID: 24360660
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prediction of intravesical recurrence of non-muscle-invasive bladder cancer by evaluation of intratumoral Foxp3+ T cells in the primary transurethral resection of bladder tumor specimens.
    Murai R; Itoh Y; Kageyama S; Nakayama M; Ishigaki H; Teramoto K; Narita M; Yoshida T; Tomita K; Kobayashi KI; Wada A; Nagasawa M; Kubota S; Ogasawara K; Kawauchi A
    PLoS One; 2018; 13(9):e0204745. PubMed ID: 30261082
    [TBL] [Abstract][Full Text] [Related]  

  • 12. EORTC Nomograms and Risk Groups for Predicting Recurrence, Progression, and Disease-specific and Overall Survival in Non-Muscle-invasive Stage Ta-T1 Urothelial Bladder Cancer Patients Treated with 1-3 Years of Maintenance Bacillus Calmette-Guérin.
    Cambier S; Sylvester RJ; Collette L; Gontero P; Brausi MA; van Andel G; Kirkels WJ; Silva FC; Oosterlinck W; Prescott S; Kirkali Z; Powell PH; de Reijke TM; Turkeri L; Collette S; Oddens J
    Eur Urol; 2016 Jan; 69(1):60-9. PubMed ID: 26210894
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Shorter recurrence-free survival time, higher risk of multiple recurrences: a retrospective study of non-muscle invasive bladder cancer after transurethral resection.
    Deng N; Chen JX; Chen LW; Qiu SP; Li XF; Wang DH
    Chin Med J (Engl); 2012 Oct; 125(20):3681-6. PubMed ID: 23075724
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dividing CKD stage 3 into G3a and G3b could better predict the prognosis of IgA nephropathy.
    Zhang JJ; Yu GZ; Zheng ZH; Liu YF; Du YY; Quan SX; Liu YJ; Lv JC; Zhang H
    PLoS One; 2017; 12(4):e0175828. PubMed ID: 28414748
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term single-institute experience with trimodal bladder-preserving therapy with proton beam therapy for muscle-invasive bladder cancer.
    Takaoka EI; Miyazaki J; Ishikawa H; Kawai K; Kimura T; Ishitsuka R; Kojima T; Kanuma R; Takizawa D; Okumura T; Sakurai H; Nishiyama H
    Jpn J Clin Oncol; 2017 Jan; 47(1):67-73. PubMed ID: 27737963
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical outcome of tumor recurrence for Ta, T1 non-muscle invasive bladder cancer from the data on registered bladder cancer patients in Japan: 1999-2001 report from the Japanese Urological Association.
    Kikuchi E; Fujimoto H; Mizutani Y; Okajima E; Koga H; Hinotsu S; Shinohara N; Oya M; Miki T;
    Int J Urol; 2009 Mar; 16(3):279-86. PubMed ID: 19207609
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of diabetes mellitus and metformin use with oncological outcomes of patients with non-muscle-invasive bladder cancer.
    Rieken M; Xylinas E; Kluth L; Crivelli JJ; Chrystal J; Faison T; Lotan Y; Karakiewicz PI; Fajkovic H; Babjuk M; Kautzky-Willer A; Bachmann A; Scherr DS; Shariat SF
    BJU Int; 2013 Dec; 112(8):1105-12. PubMed ID: 24053906
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cell-cycle markers do not improve discrimination of EORTC and CUETO risk models in predicting recurrence and progression of non-muscle-invasive high-grade bladder cancer.
    Passoni N; Gayed B; Kapur P; Sagalowsky AI; Shariat SF; Lotan Y
    Urol Oncol; 2016 Nov; 34(11):485.e7-485.e14. PubMed ID: 27637323
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preoperative anemia is associated with disease recurrence and progression in patients with non-muscle-invasive bladder cancer.
    Soria F; Moschini M; Abufaraj M; Wirth GJ; Foerster B; Gust KM; Özsoy M; Briganti A; Gontero P; Mathieu R; Rouprêt M; Karakiewicz PI; Shariat SF
    Urol Oncol; 2017 Mar; 35(3):113.e9-113.e14. PubMed ID: 27908681
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Polyamine-modulated factor-1 methylation predicts Bacillus Calmette-Guérin response in patients with high-grade non-muscle-invasive bladder carcinoma.
    Alvarez-Múgica M; Fernández-Gómez JM; Cebrian V; Fresno F; Escaf S; Sánchez-Carbayo M
    Eur Urol; 2013 Feb; 63(2):364-70. PubMed ID: 22682992
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.